Literature DB >> 15073028

HIV-1 Tat enhances Kaposi sarcoma-associated herpesvirus (KSHV) infectivity.

Yoshiyasu Aoki1, Giovanna Tosato.   

Abstract

The high frequency of Kaposi sarcoma (KS) in immunodeficiency states, particularly in patients with AIDS, has been attributed to increased replication of KS-associated herpesvirus (KSHV), a necessary cofactor for KS development. However, experimental KSHV infection of endothelial lineage cells that compose KS lesions has been difficult even in the absence of immune cells. Here we show that HIV-1 Tat protein can directly promote KSHV transmission. Full-length HIV-1 Tat and a 13-amino-acid peptide corresponding to the basic region of Tat specifically enhances the entry of KSHV into endothelial and other cells, presenting evidence for an active role of HIV-1 in the development of KSHV-associated diseases. These results can explain why AIDS-KS is more frequent and clinically more aggressive than KS in other immunodeficiency states.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15073028     DOI: 10.1182/blood-2003-07-2533

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  23 in total

Review 1.  Molecular biology of KSHV in relation to AIDS-associated oncogenesis.

Authors:  Whitney Greene; Kurt Kuhne; Fengchun Ye; Jiguo Chen; Fuchun Zhou; Xiufen Lei; Shou-Jiang Gao
Journal:  Cancer Treat Res       Date:  2007

2.  Sulfated polymannuroguluronate inhibits Tat-induced SLK cell adhesion via a novel binding site, a KKR spatial triad.

Authors:  Yan-lin Wu; Jing Ai; Jing-ming Zhao; Bing Xiong; Xiao-jie Xin; Mei-yu Geng; Xian-liang Xin; Han-dong Jiang
Journal:  Acta Pharmacol Sin       Date:  2011-04-18       Impact factor: 6.150

Review 3.  HIV/AIDS: epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease.

Authors:  Ryan J Sullivan; Liron Pantanowitz; Corey Casper; Justin Stebbing; Bruce J Dezube
Journal:  Clin Infect Dis       Date:  2008-11-01       Impact factor: 9.079

Review 4.  HIV and human herpesvirus 8 co-infection across the globe: Systematic review and meta-analysis.

Authors:  Eliane Rohner; Natascha Wyss; Zina Heg; Zully Faralli; Sam M Mbulaiteye; Urban Novak; Marcel Zwahlen; Matthias Egger; Julia Bohlius
Journal:  Int J Cancer       Date:  2015-07-28       Impact factor: 7.396

5.  Pilot study evaluating the interaction between paclitaxel and protease inhibitors in patients with human immunodeficiency virus-associated Kaposi's sarcoma: an Eastern Cooperative Oncology Group (ECOG) and AIDS Malignancy Consortium (AMC) trial.

Authors:  Mary Cianfrocca; Sandra Lee; Jamie Von Roenn; Michelle A Rudek; Bruce J Dezube; Susan E Krown; Joseph A Sparano
Journal:  Cancer Chemother Pharmacol       Date:  2011-01-05       Impact factor: 3.333

6.  Twenty-First Century Diseases: Commonly Rare and Rarely Common?

Authors:  Sylvia Daunert; Gurusingham Sitta Sittampalam; Pascal J Goldschmidt-Clermont
Journal:  Antioxid Redox Signal       Date:  2017-07-05       Impact factor: 8.401

7.  Human immunodeficiency virus type 1 Tat accelerates Kaposi sarcoma-associated herpesvirus Kaposin A-mediated tumorigenesis of transformed fibroblasts in vitro as well as in nude and immunocompetent mice.

Authors:  Xiuying Chen; Lin Cheng; Xuemei Jia; Yi Zeng; Shuihong Yao; Zhigang Lv; Di Qin; Xin Fang; Yongliang Lei; Chun Lu
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

8.  Kaposi sarcoma-associated herpes virus and response to antiretroviral therapy: a prospective study of HIV-infected adults.

Authors:  Mhairi Maskew; A Patrick MacPhail; Denise Whitby; Matthias Egger; Matthew P Fox
Journal:  J Acquir Immune Defic Syndr       Date:  2013-08-01       Impact factor: 3.731

9.  Clinical Features and Outcomes of Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV)-associated Inflammation: Prospective Characterization of KSHV Inflammatory Cytokine Syndrome (KICS).

Authors:  Mark N Polizzotto; Thomas S Uldrick; Kathleen M Wyvill; Karen Aleman; Vickie Marshall; Victoria Wang; Denise Whitby; Stefania Pittaluga; Elaine S Jaffe; Corina Millo; Giovanna Tosato; Richard F Little; Seth M Steinberg; Irini Sereti; Robert Yarchoan
Journal:  Clin Infect Dis       Date:  2015-12-12       Impact factor: 9.079

Review 10.  Cancer prevention in HIV-infected populations.

Authors:  Priscila H Goncalves; Jairo M Montezuma-Rusca; Robert Yarchoan; Thomas S Uldrick
Journal:  Semin Oncol       Date:  2015-09-08       Impact factor: 4.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.